Island Pharmaceuticals Secures Agreement Expansion With US Army Medical Research Institute of Infectious Diseases; Shares Up 3%

MT Newswires Live

Jun 10

Island Pharmaceuticals (ASX:ILA) secured an expansion to its cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases, a part of the Defense Health Agency and The Geneva Foundation for Medical Research, according to a Wednesday filing with the Australian bourse.

The expanded agreement confirms the company's planned dose optimization study evaluating Galidesivir, its treatment candidate for Marburg virus disease, the filing said.

The study is expected to start next quarter with topline results in the second half of the year, per the filing.

Shares rose 3% in morning trade on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2642416204"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642416204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642416204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 09:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642416204","market":"fut","top_or_hot":-1,"title":"Island Pharmaceuticals Secures Agreement Expansion With US Army Medical Research Institute of Infectious Diseases; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a> (ASX:ILA) secured an expansion to its cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases, a part of the Defense Health Agency and The Geneva Foundation for Medical Research, according to a Wednesday filing with the Australian bourse.</p><p>The expanded agreement confirms the company's planned dose optimization study evaluating Galidesivir, its treatment candidate for Marburg virus disease, the filing said.</p><p>The study is expected to start next quarter with topline results in the second half of the year, per the filing.</p><p>Shares rose 3% in morning trade on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Island Pharmaceuticals Secures Agreement Expansion With US Army Medical Research Institute of Infectious Diseases; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsland Pharmaceuticals Secures Agreement Expansion With US Army Medical Research Institute of Infectious Diseases; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 09:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a> (ASX:ILA) secured an expansion to its cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases, a part of the Defense Health Agency and The Geneva Foundation for Medical Research, according to a Wednesday filing with the Australian bourse.</p><p>The expanded agreement confirms the company's planned dose optimization study evaluating Galidesivir, its treatment candidate for Marburg virus disease, the filing said.</p><p>The study is expected to start next quarter with topline results in the second half of the year, per the filing.</p><p>Shares rose 3% in morning trade on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILA.AU","symbol_name":"ISLAND PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642416204","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642416204","pubTimestamp":1781054126,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Island Pharmaceuticals  secured an expansion to its cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases, a part of the Defense Health Agency and The Geneva Foundation for Medical Research, according to a Wednesday filing with the Australian bourse.The expanded agreement confirms the company's planned dose optimization study evaluating Galidesivir, its treatment candidate for Marburg virus disease, the filing said.The study is expected to start next quarter with topline results in the second half of the year, per the filing.Shares rose 3% in morning trade on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILA.AU":"ISLAND PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Island Pharmaceuticals与美国陆军传染病医学研究所扩大协议；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILA.AU":1},"content_text":"Island Pharmaceuticals (ASX:ILA) secured an expansion to its cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases, a part of the Defense Health Agency and The Geneva Foundation for Medical Research, according to a Wednesday filing with the Australian bourse.The expanded agreement confirms the company's planned dose optimization study evaluating Galidesivir, its treatment candidate for Marburg virus disease, the filing said.The study is expected to start next quarter with topline results in the second half of the year, per the filing.Shares rose 3% in morning trade on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}